Use of human epidermal growth factor receptor 2 (HER2)-targeting agents is currently the therapy of choice in the adjuvant setting for HER2+ breast cancer; the desire to improve survival rates has led to its use in the neoadjuvant setting. Still, clinicians have contrasting perceptions of the value of neoadjuvant therapy in this setting, and may not effectively interpret the clinical significance of emerging data regarding such therapy, resulting in suboptimal care. This activity features Edibaldo Silva-Lopez, MD, a surgical oncologist from the University of Nebraska Medical Center in Omaha discussing key information that frames much of the current perception about and emerging evidence on this important clinical topic.
Earn accreditation for this activity at the following location:
[ Ссылка ]
© 2015 Imedex, LLC.
